A IV Insulin drip — Competitive Intelligence Brief

A IV Insulin drip (A IV Insulin drip) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin. Area: Diabetes.

phase 1 Insulin Insulin receptor Diabetes Small molecule

Target snapshot

A IV Insulin drip (A IV Insulin drip) — American Heart Association. Insulin stimulates glucose uptake in cells

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
A IV Insulin drip TARGET	A IV Insulin drip	American Heart Association	phase 1	Insulin	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin class)

1. Eli Lilly and Company · 2 drugs in this class
2. Hospital Universitario Dr. Jose E. Gonzalez · 2 drugs in this class
3. Novo Nordisk A/S · 2 drugs in this class
4. DreaMed Diabetes · 1 drug in this class
5. Institute for Clinical and Experimental Medicine · 1 drug in this class
6. Kinderkrankenhaus auf der Bult · 1 drug in this class
7. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
8. Mackay Memorial Hospital · 1 drug in this class
9. Biodel · 1 drug in this class
10. American Heart Association · 1 drug in this class